Neoleukin Therapeutics, Inc. announced resignation of Robert Ho as Corporate Secretary to pursue another opportunity, effective March 1, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.59 USD | +1.43% | +12.43% | +119.76% |
Jun. 11 | Baird Initiates Neurogene With Outperform Rating, $54 Price Target | MT |
Jun. 03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+119.76% | 553M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Neoleukin Therapeutics, Inc. Announces Resignation of Robert Ho as Corporate Secretary, Effective March 1, 2022